Muzinich & Co.
New York-founded, London-headquartered global credit manager with a dedicated pan-European private debt platform targeting lower-mid-market SMEs across eight to ten European countries.
What they do
Muzinich manages a pan-European direct lending platform (established 2014) alongside their wider public credit franchise. Their flagship private debt strategy targets senior-secured and unitranche loans to sponsor-backed and founder-owned SMEs with EBITDA broadly in the €5–25m range, diversified across Western European markets including the UK. They also operate a parallel lending strategy — co-originating with European banks — at higher volume and lower leverage, and a smaller ELTIF vehicle aimed at pan-European retail-accessible private credit. Structures extend from first-lien senior through second lien and mezzanine to minority equity co-investment.
Where they fit in a lower-mid-market raise
Where Muzinich is the right counterparty is a UK SME sitting at the top of the lower-mid-market — broadly £8–15m facility requirement — that is PE-backed or has institutional sponsorship, operates in a resilient non-cyclical sector (healthcare, business services, software, food production), and can demonstrate EBITDA in the €5–25m band. Muzinich has a long UK deal history with both sponsor-backed and management buyout situations, maintains origination staff in London and Manchester, and has expressed explicit appetite for the UK market post-rate-cut cycle. A well-prepared corporate borrower in that bracket, coming via a PE sponsor or reputable adviser, is a credible fit.
Where they are not the fit
Below roughly £8m facility requirement, the deal is almost certainly sub-scale for Muzinich's main fund strategy, where disclosed ticket sizes run €15–50m. Asset-heavy, cyclical, or manufacturing-sector borrowers, and businesses with EBITDA below ~€5m, are outside their stated focus. Unsponsored transactions without PE or institutional backing face a higher bar. Borrowers seeking a pure relationship bank with ongoing current-account flexibility will not find that here.
Published terms
- Pricing
- Lower-mid-market retains higher relative spreads than large-cap (their thesis); fund pricing above bank senior; 2024 syndicated reopening pressured pricing
- Speed to terms
- Not published
- EBITDA floor
- From about £4.3m (€5m published)
- Sponsored or sponsorless
- Both - explicitly provides finance in both sponsored and sponsorless deals; sponsorless lower-mid-market is a stated focus
- Where they lend
- UK-wide; Manchester office targets industrial heartland outside London/SE, plus London desk
- How they decide
- Pan-European private-debt platform with UK desk; investment-committee model; origination/execution/monitoring run by UK team
- Covenants
- A loose covenant package
As published by the lender and last reviewed July 2026. Terms quoted on a deal are set by the credit, not by a published band.
What rules a deal out
Stated limits, taken from Muzinich & Co.’s own published criteria. A limit is where a lender starts from, not where it always ends: several of these move on a strong enough credit.
- Targets non-distressed solid-balance-sheet companies
- EBITDA ~£3m floor screens smaller deals
- No appetite in adult, gambling or weapons
How they sit against the category
- 15 of the 46 publish an indicative price at all; it is one of them.
Counted across the 46 private-credit & direct-lending funds in this directory, on what each one publishes. What a lender discloses and what it will do are different things.
Questions this page answers
Does Muzinich & Co. lend to companies without a private-equity sponsor?
Yes. Muzinich & Co. lends to owner-managed and sponsor-backed borrowers alike, so a company with no private-equity backer is not out of scope on that ground.
Where does Muzinich & Co. lend?
UK-wide; Manchester office targets industrial heartland outside London/SE, plus London desk.
What covenants does Muzinich & Co. set?
A loose covenant package. A covenant package is negotiated on the facility; the published style is where the negotiation starts.
What does Muzinich & Co. lend?
The published product set is uk lower-mid-market private debt.
On the record
Muzinich & Co. Limited is authorised and regulated by the FCA with firm reference number 19226, incorporated in England and Wales under company number 03852444, registered office at 8 Hanover Street, London W1S 1YQ.
Muzinich's pan-European private debt platform was established in 2014 and manages approximately US$5.5bn AUM within a total firm AUM of approximately US$36bn.
The firm's third pan-European private debt fund (Pan-European Private Debt III) raised over €1.3bn — its largest European private credit vehicle to date, surpassing predecessor funds of €706m and €800m respectively.
Pan-European Private Debt III targets a portfolio of 25–35 senior secured loans with deal sizes ranging between €15m and €50m, diversified across 8–10 European countries.
Muzinich's stated target borrower profile for European private debt is SMEs with EBITDA of €5–25m in the lower middle market.
Muzinich describes itself as 'the only independent asset manager with a broad parallel lending presence in Europe,' co-originating with more than 50 European banks.
Muzinich & Co. — Parallel Lending opinion piece (December 2024)
UK portfolio investments disclosed on the Muzinich website include Science in Sport Group (May 2026), Bullen Healthcare (September 2024), AFO Group (January 2024), Market News International (March 2023), and approximately ten further UK names dating to 2016.
Muzinich's European Private Credit ELTIF reached €194m AUM as of 31 December 2025, with 14 investments across 8 geographies.
Muzinich maintains origination offices in London and Manchester in addition to Dublin, Frankfurt, Madrid, Milan, Paris, and other European cities.
Sources: muzinich.com · muzinichprivatedebt.com
This profile is a curated reference note drawn from public sources, not financial advice or a recommendation. Appetite and terms change; a lender's fit for a given credit is established by approaching it, not inferred from a page.